Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Improve Healthcare for Elderly Using Consumption Tax: Mr Takemi
December 4, 2006
- Chuikyo Recommends NHI Prices for 17 New Products
December 4, 2006
- Prevention Important for Economy Class Syndrome: GSK Seminar
December 4, 2006
- Price Gaps Between Original and GE Drugs Provide Room for Further Cost Curtailment: Council
December 4, 2006
- Alfresa HD: Reinforced Marketing System Contributes to Strong Growth
December 4, 2006
- Companies Should Be Given Greater Freedom in Pricing New Drugs: Dr Aoki
December 4, 2006
- Industry Exchanges Opinions with Vice Minister of Health
December 4, 2006
- FJPWA Seminar
December 4, 2006
- Mediceo Paltac Holdings Aims for SGA Cost Ratio Below 6%: Mr Kumakura
December 4, 2006
- Drug Wholesaler Business Seminar
December 4, 2006
- SELF-MEDICATION NEWS IN BRIEF
December 4, 2006
- REGULATORY NEWS IN BRIEF
December 4, 2006
- Suzuken: Profits Up Due to Tough Stance in Price Negotiations
December 4, 2006
- 3 Anticancer Drug Candidates in PIIb: BI
December 4, 2006
- Toho: Historic High Net Profit "Not High Enough"
December 4, 2006
- New Clinical Trial Stimulus Plan to Be Announced in December: Mr Araki
December 4, 2006
- Top 4 Wholesalers Report Solid Growth in Sales, Profits
December 4, 2006
- R&D NEWS IN BRIEF -1-
December 4, 2006
- Covance CRU Honolulu Conducts Bridging Studies in Japanese, MD Studies: Dr Ruckle
November 27, 2006
- 46th Annual Scientific Meeting of JSNM
November 27, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…